Status:
COMPLETED
Multimodal Neuroimaging of Alcohol Cues, Cortisol Response, and Compulsive Motivation
Lead Sponsor:
Auburn University
Collaborating Sponsors:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Conditions:
Alcohol Use Disorder
Eligibility:
All Genders
21-45 years
Phase:
EARLY_PHASE1
Brief Summary
This study proposes to examine both the peripheral and central nervous system responses when light social drinkers and binge/heavy social drinkers are exposed to visual ethanol cues, followed by oral ...
Detailed Description
Results from the 2014 National Survey on Drug Use and Health show that 26% of adults in the US engaged in binge drinking in the past month (SAMHSA 2014). Why some people "mature out" of this behavior ...
Eligibility Criteria
Inclusion
- Binge/Heavy Social Drinkers (HSD): has never met DSM-IV criteria for alcohol or substance dependence; regular alcohol use over the past year of at least 10 drinks per week, including at lease one occasion per week consuming \>4 drinks (males) or \>3 drinks (females).
- Able to read and write English.
- Light Social Drinkers (LSD): has never met DSM-IV criteria for alcohol or substance dependence; regular alcohol use over the past year of 1-3 drinks per occasion, 1-3 times weekly, with no more than one occasion per month of drinking \>4 drinks (male) or \>3 drinks (females) (King et al., 2002).
- Do not meet criteria for any Axis I DSM-IV psychiatric diagnoses except for individuals with a past diagnosis of Post-Traumatic Stress Disorder, Major Depressive Disorder, or Obsessive Compulsive Disorder
- Provide negative urine toxicology screens during initial appointments and at admission for IV/fMRI sessions.
- Body Mass Index between 20-35.
- No current or former nicotine dependence.
Exclusion
- Meet current criteria for dependence on any psychoactive substance, excluding caffeine.
- Current or past history of alcohol dependence or abuse.
- Any current use of opiates or past history of opiate abuse/dependence.
- Current use of any psychoactive drugs, including anxiolytics, antidepressants, naltrexone or antabuse.
- Any psychotic disorder or current psychiatric symptoms requiring specific attention, including need for psychiatric medications for current major depression and anxiety disorders.
- Any significant current medical condition such as neurological, cardiovascular, endocrine, renal, liver, thyroid pathology; subjects on medications for any medical condition will be excluded.
- Peri and post-menopausal women, and those with hysterectomies.
- Pregnant and lactating women will be excluded.
Key Trial Info
Start Date :
May 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2021
Estimated Enrollment :
87 Patients enrolled
Trial Details
Trial ID
NCT04412824
Start Date
May 22 2020
End Date
December 31 2021
Last Update
March 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Auburn University MRI Center
Auburn, Alabama, United States, 36832